Optimizing Prostate Cancer Management: Leveraging PSMA Imaging to Enhance Treatment Strategies
 |
| Optimizing Prostate Cancer Management: Leveraging PSMA Imaging to Enhance Treatment Strategies Jason Efstathiou, MD, PhD; Brandon Mancini, MD, MBA, FACRO; Comron Hassanzadeh, MD, MPH; and Bridget Koontz, MD, FASTRO, discuss the evolving role of PSMA PET imaging in prostate cancer, examining its impact on diagnosis, disease staging, treatment decisions, and posttreatment assessment. They also review key clinical trial data, current guideline recommendations, and real-world applications of PSMA PET imaging in practice. Watch Now |
|
Featured Video |
-3.png?width=580&upscale=true&name=MarketingWS%20(1)-3.png) |
| Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions Panelists discuss how medical professionals select PSMA PET tracers based on factors such as diagnostic accuracy, tracer availability, patient-specific considerations, and logistical aspects such as half-life and production facilities. Fluorine-18 (^18F)–labeled tracers, such as ^18F-PSMA-1007, offer logistical advantages due to their longer half-life and higher image resolution, facilitating broader clinical application. |